Skip to main content
. 2018 Sep 10;14(2):40–49. doi: 10.17925/EE.2018.14.2.40

Figure 1: Kaplan-Meier estimates of time to 3-point MACE outcome (A) and cardiovascular death (B) in the EMPA-REG OUTCOME study.

Figure 1:

Reproduced with permission from Zinman et al., 2015.14 CI = confidence interval; CV = cardiovascular; EMPA-REG OUTCOME = empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes study; HR = hazard ratio; MACE = major adverse cardiac events; No. = number.